Section Arrow
MNOV.NASDAQ
- Medicinova
Quotes are at least 15-min delayed:2026/11/09 03:53 EST
Pre Market
Last
 --
-- (--)
Bid
--
Ask
--
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 1.46
+0.01 (+0.69%)
Day High 
1.48 
Prev. Close
1.45 
1-M High
1.72 
Volume 
14.35K 
Bid
--
Ask
--
Day Low
1.44 
Open
1.47 
1-M Low
1.358 
Market Cap 
71.37M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.42 
20-SMA 1.44 
50-SMA 1.79 
52-W High 3.8999 
52-W Low 1.22 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.21/-0.45
Enterprise Value
71.37M
Balance Sheet
Book Value Per Share
0.76
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
409.66K
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
KPTIKaryopharm Therapeutics Inc.0.0549-0.0052-8.65%-- 
Pre Market -- -- --
INOInovio Pharmaceuticals1.215-0.235-16.21%-- 
Pre Market -- -- --
LABTLakewood-Amedex Biotherapeutics Inc0.3863-0.1543-28.54%-- 
Pre Market -- -- --
CDTCdt Equity Inc1.31+0.464+54.85%0PE
Pre Market -- -- --
MRNAModerna254.19+12.73+5.27%-- 
Pre Market -- -- --
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.